The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Funding Opportunities

ALK Positive, LUNGevity Foundation issue RFA for lung cancer research award program

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

ALK Positive and LUNGevity Foundation have issued a Request for Application for ALK-positive Lung Cancer Research Awards to be granted in 2022. 

Letters of intent are due by Feb. 23, 2022. For those invited to submit a full application, the due date will be May 9, 2022.

Funded projects are expected to have a direct impact on the outcomes of patients with advanced ALK-positive lung cancer, but innovative proposals that address other unmet needs in the ALK-positive lung cancer space are also invited for submission. 

The ALK-positive award has no geographical restrictions; international researchers may apply. The successful applicant may receive up to $750,000 over an award term of two years.

The Request for Applications is posted on the proposalCENTRAL website here. For more information, contact Margery Jacobson at mjacobson@LUNGevity.org.

Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Tagrisso increased OS in early-stage EGFR-mutated lung cancer at eight year follow-up, ADAURA phase III trial finds

Tagrisso (osimertinib) demonstrated a sustained, clinically meaningful overall survival benefit at eight years compared to placebo in the adjuvant treatment of patients with early-stage (1B, 2, and 3A) epidermal growth factor receptor-mutated non-small cell lung cancer after complete tumor resection with curative intent, according to the updated exploratory results from the ADAURA phase III trial. 
Clinical Roundup

Ris-Rez reduced risk of death by 54% vs. topotecan in patients with relapsed SCLC, phase III trial in China finds

Hansoh Pharmaceutical Group announced positive overall survival data from ARTEMIS-008, its pivotal phase III trial in China, evaluating the B7-H3-targeted antibody-drug conjugate risvutatug rezetecan (Ris-Rez) versus topotecan in patients with relapsed small cell lung cancer whose disease progressed following platinum-based first-line therapy.
Clinical Roundup

Rybrevant + chemo delivers longest reported median OS in EGFR exon 20 insertion mutation-positive lung cancer

Patients with with advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations treated with intravenous Rybrevant (amivantamab-vmjw) plus carboplatin-pemetrexed chemotherapy achieved a median OS of nearly three years (34.3 months), compared with 27.9 months for chemotherapy alone, according to the final overall survival analysis of the phase III PAPILLON study. 
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account